Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4567891011121314...123124»
  • ||||||||||  CS2009 / CStone Pharma
    CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation (Grand Ballroom AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1742;    
    To improve the effect of ICB, VEGF inhibitors including bevacizumab, ramucirumab, lenvatinib, etc. were applied to interrupt tumor angiogenesis, hence promote vascular normalization in tumor immune microenvironment, and improve T lymphocyte infiltration...In the studies using immune competent humanized mice, J30 showed superior anti-tumor activities to its major competitors such as cadonilimab, AK112 and volrustomig...Conclusions J30 is a promising trispecific molecule for the treatment of various advanced solid tumors as a next-generation ICB. Current data supports further clinical research on CS2009.
  • ||||||||||  IO combinations meta-analysis in 1L mRCC (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_976;    
    P1, P3
    The CLEAR trial, which analyzes the combination of pembrolizumab plus lenvatinib, shows the most significantly improved survival as measured by median PFS (figure 1)...However, the final analysis of JAVELIN Renal 101 did not show a significant OS improvement from nivolumab with axitinib vs sunitinib, despite initial data releases (figure 2)...The dual IO combinations and IO plus TKI combinations evaluated demonstrated significantly better outcomes than sunitinib, suggesting a potential shift from considering sunitinib as the standard of care for 1L mRCC. However, according to the most recent JAVELIN Renal 101 updates, the OS advantage of avelumab with axitinib failed to be statistically significant compared to other IO combinations.
  • ||||||||||  CS2009 / CStone Pharma
    CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_499;    
    To improve the effect of ICB, VEGF inhibitors including bevacizumab, ramucirumab, lenvatinib, etc. were applied to interrupt tumor angiogenesis, hence promote vascular normalization in tumor immune microenvironment, and improve T lymphocyte infiltration...In the studies using immune competent humanized mice, J30 showed superior anti-tumor activities to its major competitors such as cadonilimab, AK112 and volrustomig...Conclusions J30 is a promising trispecific molecule for the treatment of various advanced solid tumors as a next-generation ICB. Current data supports further clinical research on CS2009.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Review, Journal:  Small molecule-based targeted therapy in liver cancer. (Pubmed Central) -  Oct 3, 2024   
    To date, small-molecule-based targeted therapies are highly recommended (first line: sorafenib and lenvatinib; second line: regorafenib and cabozantinib) by current the clinical guidelines of the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network...In fact, the known small molecule-based therapies still have limited clinical benefits to liver cancer patients. Therefore, we analyze the current status and give our ideas for the urgent issues and future directions in this field, suggesting the clues for novel techniques in liver cancer treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Glucose Transporter 1 Inhibitors Induce Autophagy and Synergize With Lenvatinib in Thyroid Cancer Cells. (Pubmed Central) -  Oct 3, 2024   
    Our data support this treatment option for refractory melanoma, as it is not approved by the Food and Drug Administration or European Medicines Agency, and highlight the need for new strategies. Treatment with GLUT1 inhibitors activates autophagy and provokes cell cycle arrest, accompanied by a decrease in colony formation and invasive capacity in thyroid cancer cells.
  • ||||||||||  limantrafin (CB-103) / Cellestia Biotech, Lenvima (lenvatinib) / Eisai, Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Enrollment change:  CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (clinicaltrials.gov) -  Oct 1, 2024   
    P1/2,  N=10, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=34 --> 10
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Current research status of transarterial therapies for hepatocellular carcinoma. (Pubmed Central) -  Oct 1, 2024   
    In this editorial, we comment on the article by Ma et al published in the recent issue of the World Journal of Gastro intestinal Oncology: "Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable HCC"...In the future, more studies are needed to determine the optimal transarterial local treatment for HCC. With the emergence of checkpoint immunotherapy modalities, it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients.
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    Enrollment closed:  MS100070_0087: Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors (clinicaltrials.gov) -  Oct 1, 2024   
    P1,  N=50, Active, not recruiting, 
    With the emergence of checkpoint immunotherapy modalities, it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients. Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Multimodal treatment Strategies for Advanced Hepatocellular Carcinoma: a 12-Year Follow-up Case Report (Hall Y1-Y3) -  Sep 27, 2024 - Abstract #EANM2024EANM_1043;    
    The patient was initially treated with sorafenib, which was interrupted due to relevant toxicity. In conclusion, this report highlights the benefits of a multimodal therapy approach, which are reflected in both treatment choice and timing, to achieve a personalized approach and so obtain finally , in an unfavorable prognostic scenario, as the advanced HCC, a survival exceeding 10 years.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal, Combination therapy, Metastases:  Newly established borderline resectable 1 (BR1) (Pubmed Central) -  Sep 26, 2024   
    Recruiting --> Active, not recruiting In patients with advanced HCC with intrahepatic target nodules the BR1 category is one of the favorable candidates for selecting those to be treated with MCT strategies.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker:  Protocol for analysis of plasma proteomes from patients with hepatocellular carcinoma receiving combination therapy. (Pubmed Central) -  Sep 25, 2024   
    Plasma shows distinct metabolomic and proteomic signatures in response to combination therapy with lenvatinib and anti-programmed death-1 (PD-1) antibody in treating hepatocellular carcinoma (HCC)...We then detail procedures for downstream analyses including normalization, differential expression analysis, functional enrichment analysis, correlation analysis, consensus clustering, and survival analysis. For complete details on the use and execution of this protocol, please refer to Li et
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  TALENP001: Neoadjuvant Triple Therapy for Resectable HCC (clinicaltrials.gov) -  Sep 24, 2024   
    P=N/A,  N=20, Recruiting, 
    These results suggest that TMX2 May serve as a prognostic marker and promising therapeutic target for HCC treatment. Not yet recruiting --> Recruiting
  • ||||||||||  amiloride hydrochloride / Generic mfg.
    Hypercalcemia in a Patient with Cancer on an Immune Checkpoint Inhibitor, a Tyrosine Kinase Inhibitor, and Amiloride: Which Is the Culprit? (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2475;    
    She had been recently started on pembrolizumab, an ICI, and Lenvatinib (a tyrosine kinase inhibitor [TKI])...Upon admission, amiloride was discontinued and patient received normal saline, calcitonin and pamidronate (Figure)...It is thought to occur due to membrane hyperpolarization in the setting of sodium reabsorption, thereby promoting calcium entry. It is also possible that concurrent treatment with ICIs exacerbated the hypercalcemia, as ICIs have been reported to cause hypercalcemia by endocrinopathies, sarcoid-like granuloma, humoral hypercalcemia due to parathyroid-related hormone and hyperprogressive disease following ICI initiation.
  • ||||||||||  JS201 / Shanghai Junshi Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=30, Recruiting, 
    might be valuable as novel biomarkers and targets. Trial primary completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New trial, Real-world evidence, Real-world, Metastases:  Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) (clinicaltrials.gov) -  Sep 20, 2024   
    P=N/A,  N=20, Not yet recruiting, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Journal, Adverse events:  Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system. (Pubmed Central) -  Sep 20, 2024   
    Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy...There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma.